For example, histone deacetylase and enhancer of Zeste 2 Polycomb repressive complex 2 are upregulated in BAP1-deficient tumors; therefore, targeting these genes could improve BAP1-deficient tumor sensitivity to treatment (22, 23). The gene discussed is BAP1; the disease is neoplasm.